JP2020503345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503345A5 JP2020503345A5 JP2019536086A JP2019536086A JP2020503345A5 JP 2020503345 A5 JP2020503345 A5 JP 2020503345A5 JP 2019536086 A JP2019536086 A JP 2019536086A JP 2019536086 A JP2019536086 A JP 2019536086A JP 2020503345 A5 JP2020503345 A5 JP 2020503345A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- inflammasome
- antibody
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010034143 Inflammasomes Proteins 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 4
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 claims 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 3
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 claims 3
- 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 claims 3
- 101710182264 NLR family CARD domain-containing protein 4 Proteins 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 210000004901 leucine-rich repeat Anatomy 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 210000005265 lung cell Anatomy 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102100035904 Caspase-1 Human genes 0.000 claims 2
- 108090000426 Caspase-1 Proteins 0.000 claims 2
- 108010000916 Fimbriae Proteins Proteins 0.000 claims 2
- 102100037907 High mobility group protein B1 Human genes 0.000 claims 2
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 claims 2
- 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 claims 2
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102000003810 Interleukin-18 Human genes 0.000 claims 2
- 108090000171 Interleukin-18 Proteins 0.000 claims 2
- 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 claims 2
- 102100031897 NACHT, LRR and PYD domains-containing protein 2 Human genes 0.000 claims 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 229960002897 heparin Drugs 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 102000011727 Caspases Human genes 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 claims 1
- 102100032361 Pannexin-1 Human genes 0.000 claims 1
- 101710165201 Pannexin-1 Proteins 0.000 claims 1
- 101710115313 Pyrin domain-containing protein 3 Proteins 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 239000000158 apoptosis inhibitor Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960000610 enoxaparin Drugs 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 108091006086 inhibitor proteins Proteins 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000007115 recruitment Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000008719 thickening Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022181180A JP2023016835A (ja) | 2016-12-29 | 2022-11-11 | 肺におけるインフラマソーム活性及び炎症をモジュレートする方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440180P | 2016-12-29 | 2016-12-29 | |
| US62/440,180 | 2016-12-29 | ||
| PCT/US2017/068713 WO2018126009A1 (en) | 2016-12-29 | 2017-12-28 | Method for modulating inflammasome activity and inflammation in the lung |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022181180A Division JP2023016835A (ja) | 2016-12-29 | 2022-11-11 | 肺におけるインフラマソーム活性及び炎症をモジュレートする方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020503345A JP2020503345A (ja) | 2020-01-30 |
| JP2020503345A5 true JP2020503345A5 (enExample) | 2021-02-12 |
Family
ID=62710025
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536086A Pending JP2020503345A (ja) | 2016-12-29 | 2017-12-28 | 肺におけるインフラマソーム活性及び炎症をモジュレートする方法 |
| JP2022564482A Pending JP2023515271A (ja) | 2016-12-29 | 2021-04-23 | ウイルス関連炎症を処置するための方法及び組成物 |
| JP2022181180A Pending JP2023016835A (ja) | 2016-12-29 | 2022-11-11 | 肺におけるインフラマソーム活性及び炎症をモジュレートする方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564482A Pending JP2023515271A (ja) | 2016-12-29 | 2021-04-23 | ウイルス関連炎症を処置するための方法及び組成物 |
| JP2022181180A Pending JP2023016835A (ja) | 2016-12-29 | 2022-11-11 | 肺におけるインフラマソーム活性及び炎症をモジュレートする方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20190336598A1 (enExample) |
| EP (2) | EP3562506A4 (enExample) |
| JP (3) | JP2020503345A (enExample) |
| KR (1) | KR20200013630A (enExample) |
| CN (1) | CN110461356A (enExample) |
| AU (1) | AU2017386550A1 (enExample) |
| BR (1) | BR112019013463A2 (enExample) |
| CA (2) | CA3048864A1 (enExample) |
| CO (1) | CO2019008087A2 (enExample) |
| IL (1) | IL267685A (enExample) |
| MX (1) | MX2019007916A (enExample) |
| PH (1) | PH12019501549A1 (enExample) |
| RU (1) | RU2019123160A (enExample) |
| SG (1) | SG10202106385XA (enExample) |
| WO (2) | WO2018126009A1 (enExample) |
| ZA (1) | ZA201904861B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021222263A2 (en) * | 2020-04-27 | 2021-11-04 | University Of Miami | Compositions and methods for treating inflammasome related diseases or conditions |
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| WO2018126009A1 (en) | 2016-12-29 | 2018-07-05 | University Of Miami | Method for modulating inflammasome activity and inflammation in the lung |
| SG11202013176VA (en) * | 2018-07-03 | 2021-01-28 | Univ Miami | Compositions and methods for treating inflammasome related diseases or conditions |
| EP3938781B1 (en) * | 2019-03-13 | 2025-12-10 | Fundación para la Formación e Investigación Sanitarias de la Región De Murcia (FFIS) | In vitro |
| WO2021097084A1 (en) * | 2019-11-12 | 2021-05-20 | The Uab Research Foundation | Methods for treating immunosuppression and diseases associated with immunosuppression |
| CN111363847B (zh) * | 2020-02-12 | 2021-06-29 | 广州微远医疗器械有限公司 | 基于CRISPR技术的2019-nCoV快速检测引物组及其用途 |
| CN113278730B (zh) * | 2020-02-20 | 2022-03-25 | 中元汇吉生物技术股份有限公司 | 一种新型冠状病毒检测试剂盒、用途及其使用方法 |
| US20230172933A1 (en) * | 2020-03-19 | 2023-06-08 | Nanyang Technological University | Use of a compound or composition comprising an inhibitor of nlrp1 inflammasome activation for the treatment of human airway inflammation |
| CN111289745A (zh) * | 2020-03-25 | 2020-06-16 | 中山生物工程有限公司 | 新型冠状病毒IgM抗体酶联免疫检测试剂盒及其检测方法 |
| KR102658146B1 (ko) * | 2020-03-26 | 2024-04-18 | 경북대학교 산학협력단 | Pannexin3을 포함하는 근육 손상 진단용 바이오마커 조성물 및 이를 이용한 진단방법 |
| CN111529707B (zh) * | 2020-04-29 | 2021-04-23 | 威海市立医院 | Gsdmd抑制剂在制备治疗幽门螺杆菌感染的药物中的应用 |
| CN111777684A (zh) * | 2020-06-09 | 2020-10-16 | 重庆君同生物技术有限公司 | 冠状病毒串联表位蛋白所诱导抗体的制备方法及其应用 |
| IL299793A (en) * | 2020-07-09 | 2023-03-01 | Remedy Cell Ltd | Methods for treating acute respiratory distress syndrome and cytokine storm |
| KR102582417B1 (ko) * | 2020-11-06 | 2023-09-26 | 한국과학기술원 | 인플라마솜 어댑터 단백질(asc)의 중합체화 도메인에 결합하는 신규한 폴리펩타이드 및 이의 용도 |
| AU2022211971A1 (en) | 2021-01-29 | 2023-08-10 | Illimis Therapeutics, Inc. | Fusion molecule having non-inflammatory phagocytosis inducing activity |
| CN113109569B (zh) * | 2021-03-05 | 2022-08-19 | 李朴 | Gsdmd作为生物标志物在胸腔积液相关疾病鉴别诊断及疗效评估上的用途 |
| KR102673132B1 (ko) * | 2021-04-20 | 2024-06-12 | 아주대학교산학협력단 | 염증성 질환 치료를 위한 nlrp3 인플라마좀 억제 펩타이드 |
| EP4337676A1 (en) | 2021-05-10 | 2024-03-20 | Entrada Therapeutics, Inc. | Antigen-binding and antigen degradation constructs |
| CN118119644A (zh) * | 2021-08-25 | 2024-05-31 | R.P.谢勒技术有限责任公司 | 具有人源化框架区的抗体 |
| CN115819548B (zh) * | 2021-11-16 | 2023-09-01 | 北京美德泰康生物科技有限公司 | 一种检测炎症相关疾病的标志物和方法 |
| WO2024006457A1 (en) * | 2022-06-29 | 2024-01-04 | University Of South Florida | Method of treating long-covid induced neurologic diseases |
| WO2024114906A1 (en) | 2022-11-30 | 2024-06-06 | Mabylon Ag | Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof |
| WO2024248287A1 (ko) * | 2023-06-01 | 2024-12-05 | 한양대학교 에리카산학협력단 | 결핵균 유래 폴리펩타이드를 포함하는 염증성 질환 치료용 약학 조성물 |
| WO2025081130A1 (en) * | 2023-10-12 | 2025-04-17 | University Of Miami | Use of anti-asc antibody in the treating of ocular disorders |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| CA2565063A1 (en) | 2004-04-29 | 2005-11-24 | Otsuka Pharmaceutical Co., Ltd. | Glycoprotein vi antibodies and method thereof |
| US7780963B2 (en) | 2004-10-25 | 2010-08-24 | Merck & Co., Inc. | Anti-ADDL antibodies and uses thereof |
| TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| CA2679399A1 (en) | 2007-02-27 | 2008-09-04 | Genetech, Inc. | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| WO2009014863A2 (en) * | 2007-06-29 | 2009-01-29 | Thomas Jefferson University | Asc and pyrin-asc pyroptosomes and uses thereof |
| US8685400B2 (en) * | 2007-07-30 | 2014-04-01 | University Of Miami | Modulating inflammasome activity and inflammation in the central nervous system |
| US20100150938A1 (en) * | 2008-07-03 | 2010-06-17 | University Of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| AU2010294225A1 (en) * | 2009-09-11 | 2012-04-05 | Protaffin Biotechnologie Ag | Composition for treatment of CXCL8-mediated lung inflammation |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| IT1406201B1 (it) | 2010-12-10 | 2014-02-14 | Univ Degli Studi Trieste | Biomarcatori per la diagnosi della sclerosi multipla |
| CA2826820A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Asc as marker for chronic obstructive pulmonary disease (copd) |
| WO2013119673A1 (en) | 2012-02-06 | 2013-08-15 | University Of Miami | Innate immune proteins as biomarkers for cns injury |
| TWI480044B (zh) | 2012-03-16 | 2015-04-11 | Taichung Veterans General Hospital | A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution |
| US20140314746A1 (en) * | 2013-03-13 | 2014-10-23 | Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine | Methods for treating or preventing fibrosis in subjects afflicted with scleroderma |
| KR20160005044A (ko) * | 2013-05-17 | 2016-01-13 | 제넨테크, 인크. | 염증성 장 질환의 진단 및 치료 방법 |
| WO2015016178A1 (ja) * | 2013-07-29 | 2015-02-05 | 国立大学法人鹿児島大学 | １，５－ｄ－アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬 |
| NZ722927A (en) * | 2014-01-10 | 2022-07-29 | Avalyn Pharma Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US10143709B2 (en) * | 2014-05-06 | 2018-12-04 | Indiana University Research And Technology Corporation | Use of ASC and ASC-CM to treat ARDS, SARS, and MERS |
| WO2016028699A2 (en) | 2014-08-18 | 2016-02-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biomarkers for diagnosis and management of neuro-immunological diseases |
| US20160263183A1 (en) | 2015-03-10 | 2016-09-15 | Brown University | Methods for treating lung disease |
| EP3294752B1 (en) * | 2015-05-12 | 2020-11-04 | The Regents of the University of California | Peptide treatment for inflammation and fibrosis |
| TWI743047B (zh) | 2015-08-17 | 2021-10-21 | 安成生物科技股份有限公司 | 使用雙醋瑞因或其類似物抑制asc表現、nlrp3表現、以及/或nlrp3發炎體複合物的形成之方法 |
| KR101948048B1 (ko) | 2016-12-08 | 2019-02-14 | 한양대학교 에리카산학협력단 | 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물 |
| WO2018126009A1 (en) | 2016-12-29 | 2018-07-05 | University Of Miami | Method for modulating inflammasome activity and inflammation in the lung |
| KR20200088299A (ko) | 2017-09-20 | 2020-07-22 | 더 유니버시티 오브 마이애미 | 신경학적 장애의 바이오마커로서 인플라마솜 단백질의 검출 방법 |
| SG11202013176VA (en) | 2018-07-03 | 2021-01-28 | Univ Miami | Compositions and methods for treating inflammasome related diseases or conditions |
-
2017
- 2017-12-28 WO PCT/US2017/068713 patent/WO2018126009A1/en not_active Ceased
- 2017-12-28 US US16/474,708 patent/US20190336598A1/en not_active Abandoned
- 2017-12-28 BR BR112019013463-8A patent/BR112019013463A2/pt unknown
- 2017-12-28 CA CA3048864A patent/CA3048864A1/en active Pending
- 2017-12-28 KR KR1020197022320A patent/KR20200013630A/ko not_active Ceased
- 2017-12-28 CN CN201780087090.4A patent/CN110461356A/zh active Pending
- 2017-12-28 EP EP17888678.4A patent/EP3562506A4/en not_active Withdrawn
- 2017-12-28 AU AU2017386550A patent/AU2017386550A1/en not_active Abandoned
- 2017-12-28 JP JP2019536086A patent/JP2020503345A/ja active Pending
- 2017-12-28 RU RU2019123160A patent/RU2019123160A/ru unknown
- 2017-12-28 SG SG10202106385XA patent/SG10202106385XA/en unknown
- 2017-12-28 MX MX2019007916A patent/MX2019007916A/es unknown
-
2018
- 2018-07-03 US US16/026,482 patent/US10703811B2/en active Active
-
2019
- 2019-06-26 IL IL267685A patent/IL267685A/en unknown
- 2019-07-01 PH PH12019501549A patent/PH12019501549A1/en unknown
- 2019-07-24 ZA ZA2019/04861A patent/ZA201904861B/en unknown
- 2019-07-25 CO CONC2019/0008087A patent/CO2019008087A2/es unknown
-
2020
- 2020-04-13 US US16/847,054 patent/US10961306B2/en active Active
- 2020-04-23 US US16/856,407 patent/US11174307B2/en active Active
-
2021
- 2021-04-23 WO PCT/US2021/028847 patent/WO2021217004A2/en not_active Ceased
- 2021-04-23 EP EP21792075.0A patent/EP4139348A4/en active Pending
- 2021-04-23 CA CA3176518A patent/CA3176518A1/en active Pending
- 2021-04-23 JP JP2022564482A patent/JP2023515271A/ja active Pending
- 2021-06-25 US US17/358,582 patent/US20210324065A1/en not_active Abandoned
-
2022
- 2022-11-11 JP JP2022181180A patent/JP2023016835A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503345A5 (enExample) | ||
| RU2019123160A (ru) | Способ модуляции активности инфламмасом и воспаления в легком | |
| CY1123391T1 (el) | (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι | |
| JP2014518275A5 (enExample) | ||
| JP2011184466A5 (enExample) | ||
| JP2014523884A5 (enExample) | ||
| PH12015502581B1 (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
| JP2015502346A5 (enExample) | ||
| JP2014074046A5 (enExample) | ||
| JP2011504474A5 (enExample) | ||
| JP2019520550A5 (enExample) | ||
| EA201001821A1 (ru) | Производные триазола, полезные для лечения заболеваний | |
| JP2015517489A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| Mallia et al. | Neutrophil adhesion molecules in experimental rhinovirus infection in COPD | |
| JP2020507587A5 (enExample) | ||
| EA201891931A1 (ru) | Новые ингибиторы фосфатидилинозитол-3-киназы гамма | |
| JP2016128399A5 (enExample) | ||
| JP2017522288A5 (enExample) | ||
| ZA202201828B (en) | Therapeutic fusion proteins | |
| Wu et al. | Inhibitory effects of simvastatin on staphylococcus aureus lipoteichoic acid-induced inflammation in human alveolar macrophages | |
| JP2015511625A5 (enExample) | ||
| BR112014006473A2 (pt) | composição e método para tratamento de uma doença autoimune | |
| JP7688910B2 (ja) | 線維化、炎症、及び／又は老化疾患に対する治療薬 | |
| NO20054876L (no) | Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser |